Jocasta Neuroscience
Jocasta Neuroscience raises $35M Series A at $150M valuation
Jocasta Neuroscience: Series A Funding Round
Jocasta Neuroscience has successfully raised $35M in Series A funding, reaching a valuation of $150M.
Company Overview
Developing longevity protein for neurodegenerative conditions
Funding Details
The Series A round was led by Andreessen Horowitz bio, with participation from Khosla Ventures.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2023
- Employees: 50+
- Category: Biotech
Investment
Jocasta Neuroscience plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Andreessen Horowitz bio: Verified investor in Series A
- Khosla Ventures: Verified investor in Series A
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free